Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes medicines for oncology, inflammation, and other therapeutic areas. The company generates revenue primarily from direct sales of marketed products—particularly JAKAFI (a JAK inhibitor for myelofibrosis and polycythemia vera), OPZELURA (a topical treatment for atopic dermatitis), PEMAZYRE (for cholangiocarcinoma), and ICLUSIG (for chronic myeloid leukemia)—as well as from royalties and milestone payments on products licensed to partners including Novartis and Eli Lilly. Incyte operates globally through its own commercial infrastructure and manufacturing facilities, and maintains a clinical pipeline of drug candidates in development to expand its therapeutic reach and diversify its revenue base.